Castle Biosciences (CSTL) Research & Development (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Research & Development data on file, last reported at $14.4 million in Q1 2026.

• Quarterly Research & Development rose 14.62% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.7 million (up 5.65% YoY) and the FY2025 annual result came in at $51.8 million, changed 0.37% from the prior year.
• Research & Development improved to $14.4 million in Q1 2026 per CSTL's latest filing, from $13.5 million in the prior quarter.
• The five-year high for Research & Development was $14.4 million in Q1 2026, with the low at $10.8 million in Q1 2022.
• Average Research & Development over 5 years is $12.8 million, with a median of $12.9 million recorded in 2023.
• Year-over-year, Research & Development jumped 82.14% in 2022 and decreased 9.54% in 2025.
• Castle Biosciences' Research & Development stood at $11.3 million in 2022, then climbed by 14.9% to $13.0 million in 2023, then fell by 9.4% to $11.8 million in 2024, then increased by 14.8% to $13.5 million in 2025, then climbed by 6.76% to $14.4 million in 2026.
• Business Quant data shows CSTL's Research & Development at $14.4 million in Q1 2026, $13.5 million in Q4 2025, and $13.0 million in Q3 2025.